Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × R-CHOP protocol × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Recurrence 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 12 Cyclophosphamide 12 pembrolizumab 11 Rituximab 11 venetoclax 9 fludarabine 9 pomalidomide 8 Lenalidomide 7 Gemcitabine 6 Cytarabine 6 Calcium Dobesilate 6 glofitamab 5 Temozolomide 5 Nivolumab 5 Etoposide 5 Bevacizumab 5 selinexor 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Doxorubicin 4 Capecitabine 4 Azacitidine 4 zanubrutinib 3 tisagenlecleucel 3 elotuzumab 3 belantamab mafodotin 3 atezolizumab 3 Vincristine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05888493 2026-02-20

LEDA

Novartis

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡